oral glp 1 inhibitors GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies Novo Nordisk's oral GLP-1 drug

California, North Carolina, and several New England states now cover semaglutide for patients with type 2 diabetes and a BMI above 30, while a smaller subset of programs extend coverage to include weight management indications

Oral formulations need higher doses to produce the same blood levels the injectable achieves at lower doses - and higher doses mean higher manufacturing costs

That stress leads to: Hormonal shifts (thyroid, cortisol, sex hormones) Lower circulating nutrients (especially iron, zinc, and B-vitamins) Reduced caloric and protein intake Each of these is enough to trigger TE on its own

doi: 10.1038/nrneph.2015.173

Ongoing and planned trials (Supplementary Table 3

Proposals should be made to the corresponding author and will be reviewed by the Birmingham Clinical Trials Unit Data Sharing Committee in discussion with the Chief Investigator